AAV-CXCL9 Combination Immunotherapy: A Promising Strategy in the Treatment of Glioblastoma
Investigators at the University of Florida Brain Tumor Immunotherapy Program developed a novel immunotherapy combining AAV gene therapy and anti-PD-1 immune checkpoint blockade to overcome immune suppression in glioblastoma.